Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules

Rhea-AI Summary

Windtree Therapeutics (WINT) has successfully regained compliance with Nasdaq's minimum bid price requirement, following a notice of non-compliance received on December 4, 2024. The biotechnology company, which focuses on developing innovative therapies for critical conditions, had failed to maintain a closing bid price of $1.00 or more for 30 consecutive trading days.

To regain compliance, WINT needed to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. The company achieved this requirement, maintaining the required bid price since February 21, 2025. Windtree will remain under a mandatory panel monitor until March 20, 2026.

Positive

• Regained Nasdaq listing compliance, avoiding potential delisting risk

Negative

• Company remains under mandatory panel monitor until March 2026, indicating continued scrutiny

WARRINGTON, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that the Company received notice from The Nasdaq Stock Market LLC ("Nasdaq") that Windtree has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq. The Company will be subject to a mandatory panel monitor until March 20, 2026.

The Company was previously notified by Nasdaq on December 4, 2024 that it was not in compliance with the minimum bid price rule because its common stock failed to meet the closing bid price of $1.00 or more for 30 consecutive trading days, as required by the Nasdaq Listing Rules. To regain compliance with the rule, the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. Nasdaq noted that this requirement was met and had been exhibited by a closing bid price of more than $1.00 since February 21, 2025.

About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree’s portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place.

Forward-Looking Statements
This press release contains statements related to the potential clinical effects of istaroxime; the potential benefits and safety of istaroxime; and the clinical development of istaroxime. Such statements constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include, among other things: the Company’s ability to acquire revenue generating subsidiaries; the market’s reaction to potential acquisitions by the Company; the Company’s ability to secure significant additional capital as and when needed; the Company’s ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company’s risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company’s other product candidates, including preclinical oncology candidates; the Company’s ability to access the debt or equity markets; the Company’s ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company’s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company’s product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company’s efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company’s product candidates, if approved; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People’s Republic of China and the Republic of China (Taiwan), and the evolving events in the Middle East, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company’s operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company’s ability to access the capital markets. These and other risks are described in the Company’s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. 

Contact Information:

Eric Curtis
ecurtis@windtreetx.com

FAQ

When did Windtree Therapeutics (WINT) regain Nasdaq compliance?

Windtree regained compliance with Nasdaq's minimum bid price requirement after maintaining a closing bid price above $1.00 since February 21, 2025.

What was the reason for WINT's Nasdaq non-compliance notice in December 2024?

WINT received a non-compliance notice on December 4, 2024, for failing to maintain a closing bid price of $1.00 or more for 30 consecutive trading days.

How long will WINT be under Nasdaq's mandatory panel monitor?

Windtree will be subject to Nasdaq's mandatory panel monitor until March 20, 2026.

What requirements did WINT meet to regain Nasdaq compliance?

WINT had to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days.